title: Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.
abstract: Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over 25 years. It is a safe preparation with no long-term side effects. IVIg was first demonstrated to be effective in autoimmune disorders, two decades ago, in the treatment of acute immune thrombocytopenia. Since then, the therapeutic efficacy of IVIg has been established in Guillain Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), dermatomyositis (DM), Kawasaki syndrome and the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants and reported in a large number of other autoimmune and systemic inflammatory conditions.
authors.affiliation: INSERM U681, Université Pierre et Marie Curie Institut des Cordeliers, 15 rue de l'Ecole de Médecine, Paris, France.
authors.forename: Namita
authors.initials: N
authors.lastname: Misra
authors.forename: Jagadeesh
authors.initials: J
authors.lastname: Bayry
authors.forename: Amal
authors.initials: A
authors.lastname: Ephrem
authors.forename: Suryasarathi
authors.initials: S
authors.lastname: Dasgupta
authors.forename: Sandrine
authors.initials: S
authors.lastname: Delignat
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Duong Van Huyen
authors.forename: Fabienne
authors.initials: F
authors.lastname: Prost
authors.forename: Sebastien
authors.initials: S
authors.lastname: Lacroix-Desmazes
authors.forename: Antonino
authors.initials: A
authors.lastname: Nicoletti
authors.forename: Michel D
authors.initials: MD
authors.lastname: Kazatchkine
authors.forename: Srini V
authors.initials: SV
authors.lastname: Kaveri
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D003165:Complement System Proteins / Q000502:physiology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009186:Myelin Sheath / Q000502:physiology; D009422:Nervous System Diseases / Q000628:therapy*; D011961:Receptors, Fc / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D001323:Autoantibodies; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D011961:Receptors, Fc; D003165:Complement System Proteins